FDCDDQ
STML

Federation des caisses Desjardins du Quebec’s Stemline Therapeutics, Inc. STML Stock Holding History

Federation des caisses Desjardins du Quebec’s Portfolio STML Stock Details STML Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-330
Closed -$5.48K – 2172
2018
Q3 		$5.48K Hold
330
– – ﹤0.01% 1862
2018
Q2 		$5.3K Buy
+330
New +$5.89K ﹤0.01% 1888

Other funds holding STML

PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Manulife (Manufacturers Life Insurance)
Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
LSC
Lyon Street Capital Sausalito, California $67M AUM
NC
Nexthera Capital New York $120M AUM 10.01% 1-Year Est. Return

Federation des caisses Desjardins du Quebec's STML Position: Q4 2018 in Review

Federation des caisses Desjardins du Quebec sold out of Stemline Therapeutics, Inc. (STML) in Q4 2018, closing a stake of 330 shares — an estimated $5.48K sold.

Federation des caisses Desjardins du Quebec first reported a position in STML in Q2 2018 and held it in 2 quarters. The position peaked at $5.48K in Q3 2018. 92 funds tracked by Wall St. Rank hold STML as of Q4 2018.

  • Federation des caisses Desjardins du Quebec reported no remaining Stemline Therapeutics, Inc. position as of Q4 2018 after selling out during the quarter.
  • Federation des caisses Desjardins du Quebec sold 330 Stemline Therapeutics, Inc. shares in Q4 2018, an estimated $5.48K.
  • Federation des caisses Desjardins du Quebec first reported a position in Stemline Therapeutics, Inc. in Q2 2018 and held it in 2 quarters.
  • Federation des caisses Desjardins du Quebec's Stemline Therapeutics, Inc. position peaked at $5.48K in Q3 2018.
  • 92 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q4 2018.

Based on Federation des caisses Desjardins du Quebec's 13F filing for Q4 2018, filed 30 Aug 2024.